Nuwellis, Inc. Common Stock

Day range

$0.28 – $0.36

Open

$0.31

Prev close

$0.32

Volume

658.35K

Market cap

$1.17M

Shares out

4.87M

P/E

—

P/S

0.13

P/B

-0.57

P/FCF

—

ROE

550.8%

ROA

-124.0%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Stock splitOct 23, 2026

  On October 13, 2026, the Board approved a one-for-nine reverse stock split of the Company's issued and outstanding shares of common stock (the "Reverse Stock Split"). ... The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on October 26, 2026, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on October 27, 2026.

• Investor presentationAug 26, 2026

  On August 25, 2026, Nuwellis, Inc. (the "Company") posted an updated corporate presentation to its website at ir.nuwellis.com, which the Company may use from time to time in presentations, investor communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

• Underwriting agreementAug 3, 2026

  In connection with the Offerings, the Company also entered into a placement agency agreement, dated July 31, 2026 (the "Placement Agency Agreement"), with Ladenburg Thalmann & Co. Inc. (the "Placement Agent"), pursuant to which the Company agreed to pay the Placement Agent a cash fee equal to 9.0% of the aggregate gross proceeds of the Offerings, and reimburse the Placement Agent for certain expenses and legal fees. The Company also agreed to issue to the Placement Agent warrants (the "Placement Agent Warrants") to purchase shares of Common Stock (the "Placement Agent Warrant Shares"), equal to 3.0% of the aggregate number of shares of Common Stock issued in the Offerings.

• Warrant or conversionJul 24, 2026

  To approve the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635(d) and Nasdaq's interpretations and guidance thereunder pursuant to the exercise of warrants sold in our financing transaction that closed on June 8, 2026 and outstanding warrants that were repriced in connection therewith.

• Stock splitJun 24, 2026

  On June 16, 2026, the Board approved a one-for-thirty-five reverse stock split of the Company's issued and outstanding shares of common stock (the 'Reverse Stock Split'). On June 23, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the 'Certificate of Amendment') to effect the Reverse Stock Split. The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on June 25, 2026, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on June 26, 2026. When the Reverse Stock Split becomes effective, every 35 shares of the Company's issued and outstanding common stock (and such shares held in treasury) will automatically be converted into one share of common stock.

Days to cover

1.0

Short interest

167.44K

Avg volume

5.68M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical
  positiveGlobeNewswire Inc.· Aug 25, 2026
• Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
  neutralGlobeNewswire Inc.· Jul 31, 2026
• Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)
  positiveGlobeNewswire Inc.· Jun 26, 2026
• Nuwellis Announces Closing of $6.0 Million Registered Public Offering
  neutralBenzinga· Jun 8, 2026
• Nuwellis Announces Closing of $6.0 Million Registered Public Offering
  neutralGlobeNewswire Inc.· Jun 8, 2026